Literature DB >> 29072258

A metabolic mechanism analysis of Fuzheng-Huayu formula for improving liver cirrhosis with traditional Chinese medicine syndromes.

Ya-Nan Song1, Jian Chen1, Fei-Fei Cai1, Yi-Yu Lu1, Qi-Long Chen1, Yong-Yu Zhang2, Ping Liu3, Shi-Bing Su1.   

Abstract

Fuzheng-Huayu formula (FZHY), a Chinese herbal mixture prescription, has been proven effective in treating liver fibrosis and cirrhosis in both clinical trials and animal experiments. In this study we assessed the metabolic mechanisms of traditional Chinese medicine (TCM) syndrome-based FZHY treatment in liver cirrhosis (LC). A total of 113 participants, including 50 healthy controls and 63 LC patients, were recruited. According to the diagnosis and differentiation of the TCM syndromes, the LC patients were classified into 5 TCM syndrome groups including the liver stagnation syndrome (LSS), spleen deficiency and damp overabundance syndrome (SDDOS), damp-heat accumulation syndrome (DHAS), liver-kidney Yin deficiency syndrome (LKYDS), and blood stagnation syndrome (BSS), and administered FZHY for 6 months. FZHY treatment significantly decreased serum levels of hyaluronic acid (HA), a biochemical marker for LC, as well as TCM syndrome scores (the TCM syndrome scores were decreased in all the groups with significant decreases in the LSS and LKYDS groups). Furthermore, FZHY treatment gradually shifted the metabolic profiles of LC patients from a pathologic state to a healthy state, especially in LC patients with LSS and LKYDS. Twenty-two differently altered metabolites (DAMs) were identified, including carbohydrates, amino acids, fatty acids, etc with 9 DAMs in LSS patients, 9 in LKYDS patients, and 4 in other patients. The metabolic pathways involved in the conversion of amino acids and the body's detoxification process were regulated first, followed by the pathways involved in the body's energy supply process. In conclusion, the evaluation of the effect of TCM syndrome-based FZHY treatment show that FZHY has a better effect on LKYDS and LSS than on the other TCM syndromes, and the metabolic mechanisms might be involved in the increased detoxification function in LKYDS and the improvement of energy supply in LSS, which provides important evidence for the clinical application of TCM syndrome-based treatment.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29072258      PMCID: PMC6256279          DOI: 10.1038/aps.2017.101

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  22 in total

Review 1.  'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data.

Authors:  J K Nicholson; J C Lindon; E Holmes
Journal:  Xenobiotica       Date:  1999-11       Impact factor: 1.908

2.  [Guideline for the diagnosis and treatment of liver fibrosis with integrative medicine].

Authors: 
Journal:  Zhong Xi Yi Jie He Xue Bao       Date:  2006-11

3.  Effects of Fuzheng Huayu 319 recipe on liver fibrosis in chronic hepatitis B.

Authors:  Ping Liu; Cheng Liu; Lie-Ming Xu; Yi-Yang Hu; Hui-Ming Xue; Cheng-Hai Liu; Zhi-Qing Zhang
Journal:  World J Gastroenterol       Date:  1998-08       Impact factor: 5.742

4.  Comparative pharmacokinetic and tissue distribution profiles of four major bioactive components in normal and hepatic fibrosis rats after oral administration of Fuzheng Huayu recipe.

Authors:  Tao Yang; Shan Liu; Chang-Hong Wang; Yan-Yan Tao; Hua Zhou; Cheng-Hai Liu
Journal:  J Pharm Biomed Anal       Date:  2015-05-27       Impact factor: 3.935

5.  Hepatic detoxification and hepatic function in chronic active hepatitis with and without cirrhosis.

Authors:  D Müting; J F Kalk; R Fischer; H Wuzel; J Reikowski
Journal:  Dig Dis Sci       Date:  1988-01       Impact factor: 3.199

6.  Chinese medicine CGA formula ameliorates DMN-induced liver fibrosis in rats via inhibiting MMP2/9, TIMP1/2 and the TGF-β/Smad signaling pathways.

Authors:  Xue-Mei Li; Jing-Hua Peng; Zhao-Lin Sun; Hua-Jie Tian; Xiao-Hua Duan; Lin Liu; Xin Ma; Qin Feng; Ping Liu; Yi-Yang Hu
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

7.  Free fatty acid as a marker of energy malnutrition in liver cirrhosis.

Authors:  Tatsunori Hanai; Makoto Shiraki; Kayoko Nishimura; Kenji Imai; Atsushi Suetsugu; Koji Takai; Masahito Shimizu; Takafumi Naiki; Hisataka Moriwaki
Journal:  Hepatol Res       Date:  2013-04-18       Impact factor: 4.288

8.  Classification of Traditional Chinese Medicine Syndromes in Patients with Chronic Hepatitis B by SELDI-Based ProteinChip Analysis.

Authors:  Ya-Nan Song; Hui Zhang; Yan Guan; Jing-Hua Peng; Yi-Yu Lu; Yi-Yang Hu; Shi-Bing Su
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-30       Impact factor: 2.629

9.  Transcriptional Profiling and miRNA-Target Network Analysis Identify Potential Biomarkers for Efficacy Evaluation of Fuzheng-Huayu Formula-Treated Hepatitis B Caused Liver Cirrhosis.

Authors:  Qilong Chen; Feizhen Wu; Mei Wang; Shu Dong; Yamin Liu; Yiyu Lu; Yanan Song; Qianmei Zhou; Ping Liu; Yunquan Luo; Shibing Su
Journal:  Int J Mol Sci       Date:  2016-06-03       Impact factor: 5.923

10.  Fuzheng Huayu Recipe Ameliorates Liver Fibrosis by Restoring Balance between Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Hepatic Stellate Cells.

Authors:  Qin Pan; Yu-Qin Wang; Guang-Ming Li; Xiao-Yan Duan; Jian-Gao Fan
Journal:  Biomed Res Int       Date:  2015-12-31       Impact factor: 3.411

View more
  7 in total

1.  New omic and network paradigms for deep understanding of therapeutic mechanisms for Fangji of traditional Chinese medicine.

Authors:  Dayue Darrel Duan; Zhong Wang; Yong-Yan Wang
Journal:  Acta Pharmacol Sin       Date:  2018-06       Impact factor: 6.150

2.  Traditional Chinese medicine Yiqi Huoxue recipe attenuates hepatic fibrosis via YAP/TAZ signaling.

Authors:  Wen Zhao; Xiaoxiao Zhang; Mengmeng Hou; Yuguo Zhang; Yuhui Tang; Lu Li; Shiming Dong; Lingdi Liu; Dandan Zhao; Wencong Li; Yuemin Nan
Journal:  Histol Histopathol       Date:  2021-09-07       Impact factor: 2.303

Review 3.  Research Progress of Traditional Chinese Medicine in Treatment of Myocardial fibrosis.

Authors:  Chunzhen Ren; Kai Liu; Xinke Zhao; Huan Guo; Yali Luo; Juan Chang; Xiang Gao; Xinfang Lv; Xiaodong Zhi; Xue Wu; Hugang Jiang; Qilin Chen; Yingdong Li
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

4.  Analysis of plasma metabolic profile, characteristics and enzymes in the progression from chronic hepatitis B to hepatocellular carcinoma.

Authors:  Fei-Fei Cai; Ya-Nan Song; Yi-Yu Lu; Yongyu Zhang; Yi-Yang Hu; Shi-Bing Su
Journal:  Aging (Albany NY)       Date:  2020-07-23       Impact factor: 5.682

5.  Classification of Gan Dan Shi Re Pattern and Gan Shen Yin Xu Pattern in Patients with Hepatitis B Cirrhosis Using Metabonomics.

Authors:  Chao-Qun Zhao; Long Chen; Hong Cai; Wei-Li Yao; Qun Zhou; Hui-Ming Zhu; Yue Gao; Ping Liu; Xiao-Jun Gou; Hua Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2018-11-21       Impact factor: 2.629

Review 6.  Molecular Mechanism Contributing to Malnutrition and Sarcopenia in Patients with Liver Cirrhosis.

Authors:  Fatuma Meyer; Karen Bannert; Mats Wiese; Susanne Esau; Lea F Sautter; Luise Ehlers; Ali A Aghdassi; Cornelia C Metges; Leif-A Garbe; Robert Jaster; Markus M Lerch; Georg Lamprecht; Luzia Valentini
Journal:  Int J Mol Sci       Date:  2020-07-28       Impact factor: 5.923

7.  Uncovering the Pharmacological Mechanisms of Gexia-Zhuyu Formula (GXZY) in Treating Liver Cirrhosis by an Integrative Pharmacology Strategy.

Authors:  Xu Cao; Yijun Liang; Ruijia Liu; Xiaobin Zao; Jiaying Zhang; Guang Chen; Ruijie Liu; Hening Chen; Yannan He; Jiaxin Zhang; Yong'an Ye
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.